Инжеста

Quick links to important sections

Инжеста

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Инжеста

Quick Facts

Property Description
Active ingredient Прогестерон (Progesterone)
Form Раствор для внутримышечного введения (Solution for intramuscular injection)
Pharmacological class Гестаген (Progestogen)
Common use Support of hormonal balance and поддержание беременности (pregnancy maintenance)
Origin Chemically identical to a природный гормон (natural hormone)

What Type of Medicine is Инжеста?

Инжеста is a prescription Монопрепарат classified as a Гормональное средство belonging to the Гестаген (Progestogen) pharmacological class. The active ingredient is Прогестерон (Progesterone), a Стероидный гормон essential for reproductive function.

This single-component hormonal agent is utilized to supplement the body's primary female sex hormone, addressing conditions linked to its deficiency. The classification of Progesterone within the Anatomical Therapeutic Chemical (ATC) system identifies its pharmacological function as a modulator of the genital system. This classification underscores its role in addressing hormonal balance as a рецептурный препарат (prescription-only drug).

Прогестерон: Origin, Composition, and Drug Form

The Прогестерон in Инжеста is chemically identical to the эндогенный прогестерон (endogenous progesterone), distinguishing it as a природный гормон rather than a synthetic progestin.

Инжеста is prepared as a sterile Масляный раствор (Oil solution) for injection, supplied in Ампулы as a Раствор для внутримышечного введения. This dosage form utilizes a vegetable oil base as an excipient. This design choice facilitates the slow and sustained absorption of the active ingredient into the bloodstream following its Внутримышечное (Intramuscular) administration, ensuring continuous hormonal availability for physiological support. The injectable form differentiates it from oral or topical formulations, providing a route for systemic delivery.

General Purpose of Инжеста (Progesterone)

The general purpose of Инжеста is to supplement Прогестерон levels and induce specific physiological changes in the uterus necessary for reproductive function.

Прогестерон plays a primary role in regulating the uterine lining (эндометрий), promoting its transition into the секреторная фаза to prepare the site for potential implantation. The overall therapeutic goal of this Гестаген is centered on correcting a дефицит прогестерона (progesterone deficiency), assisting in the регуляция менструального цикла (menstrual cycle regulation) and providing necessary hormonal support for поддержание беременности (pregnancy maintenance).

Regulatory References

  1. MedlinePlus Progesterone Test

What side effects are possible with Инжеста?

Possible Side Effects and Safety Information

The safety profile for Инжеста (Progesterone injection) is structured by regulatory documents based on the frequency and the System-Organ Class (SOC) of the reported adverse reactions, consistent with official government prescribing information.


Frequency Classification and Common Effects

Adverse reactions are organized based on the likelihood of their occurrence, as seen in regulatory sources:

Classification Examples of Documented Effects
Very Common (ge 1/10) Mood changes (emotional lability), insomnia, and reactions at the injection site (pain, redness, swelling)
Common (ge 1/100 to <1/10) Headache, somnolence (drowsiness), fatigue, nausea, breast tenderness, and irregular uterine bleeding

These effects primarily affect the General Disorders and Administration Site Conditions, Nervous System, and Reproductive System SOC groupings.


Serious Adverse Reactions and Safety Constraints

The official labeling documents highlight risks classified as serious. The most notable are Arterial and Venous Thromboembolic Disorders (including Deep Vein Thrombosis and Pulmonary Embolism) and Cholestatic Jaundice (a form of liver dysfunction). Patients with a history of active thromboembolic disease or severe hepatic impairment face a formal contraindication for its use.

Further constraints include caution for those with cardiac or renal dysfunction due to the potential for fluid retention. Additionally, regulatory documents note that the abrupt discontinuation of Progesterone may be associated with increased anxiety or seizure susceptibility, a key duration-related safety pattern.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents describing overdose situations for Прогестерон Injection focus on specific clinical manifestations and mandated emergency responses. Overdose exposure is documented to primarily affect the Central Nervous System (CNS), which guides the classification and required action.

Documented Overdose Presentations

The manifestations explicitly listed in official labeling include somnolence (drowsiness), dizziness, and euphoria. Additionally, some regulatory documents list dysmenorrhoea (painful menstruation) as a potential sign. These clinical signs represent the documented presentation of excessive doses of the medicine.

When to Seek Urgent Help

It is officially required to seek immediate medical attention for a suspected overdose. Urgent help must be sought by contacting emergency services immediately if the affected person exhibits severe or life-threatening outcomes, such as a seizure, collapse, trouble breathing, or unresponsiveness (inability to be awakened).

Official Management Strategy

The regulatory documents outline that the treatment of overdose consists of discontinuation of Прогестерон and the institution of appropriate symptomatic and supportive care. The required management strategy involves observation of the patient. This approach is mandated because no specific antidote is known for acute overdose situations, and treatment is confined to managing the observed symptoms. No population-specific overdose manifestations are explicitly described in the acute overdose sections of regulatory labels.

Therapeutic Uses of Инжеста

What Инжеста treats: Main Uses and Benefits

The therapeutic use of this medication's category encompasses conditions involving episodic or fluctuating manifestations, where symptoms may be associated with conditions marked by increased physiological stress or periods of heightened systemic burden.

Easing Discomfort and Supporting Stability

Инжеста is commonly used when symptoms intensify or create noticeable physiological strain, helping to ease the overall symptom burden. It provides symptomatic assistance relevant for managing conditions such as those characterized by irregular menstrual cycles or the need for supportive care related to hormone replacement therapy. In these scenarios, the medicine contributes to improved comfort and may help patients cope more steadily with symptom fluctuations.

It is often applied during phases when short-term symptomatic assistance is needed. This application supports the patient during difficult episodes by easing distress and assists with maintaining a sense of functional stability during periods of heightened discomfort.


Quick Fact: Relief for Symptom Clusters

The medicine is relevant for easing groups of symptoms related to physical discomfort and systemic imbalance that become more disruptive during flare-ups.

Eligibility and Restrictions for Use

Official Eligibility Profile

The use of Инжеста (Progesterone injection) is strictly governed by specific population eligibility rules documented in official regulatory sources.

Classification Eligibility Status Specific Conditions or Restrictions
Contraindicated Populations Must Not Use History of thromboembolic disorders (e.g., blood clots), severe liver disease, known or suspected malignancy of the breast or genital organs, undiagnosed vaginal bleeding, or a known missed abortion [FDA, EMA].
Age-Related Status Not Established Safety and effectiveness have not been established for use in pediatric patients (under 18) or geriatric patients (over 65) [FDA].
Conditional Use (Caution) Requires Monitoring Patients with renal dysfunction (kidney impairment), diabetes, or conditions influenced by fluid retention (e.g., epilepsy, migraine, cardiac dysfunction) require careful observation [FDA].
Pregnancy/Lactation Restricted Generally contraindicated in confirmed pregnancy, except for use in luteal phase support during approved Assisted Reproductive Technology (ART) protocols. The drug is detectable in nursing mothers’ milk [FDA].

These official statements define that the medicine is excluded for individuals with severe pre-existing cardiovascular and hepatic conditions. For all other populations, use is either established (adult women for specific indications), conditional, or not established (age extremes).

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the formally documented interaction patterns of Progesterone (the active ingredient in Инжеста) as described in official government regulatory documents.


Pharmacokinetic Interactions

Interactions that alter the plasma concentration of progesterone are primarily enzyme-mediated:

  • Increased Progesterone Exposure: Co-administration with CYP3A4 inhibitors (e.g., Ketoconazole) may result in an increase in progesterone's bioavailability and plasma concentration, as documented in regulatory information.
  • Decreased Progesterone Action: Concomitant use with hepatic enzyme inducers (e.g., Rifampin, Carbamazepine, Barbiturates) may cause an increased elimination of progesterone, which is associated with a reduction of its documented action.

Pharmacodynamic Interactions

Progesterone may cause specific alterations in the effects of co-administered medicines, as stated in regulatory documents:

  • Effect Enhancement: The actions of diuretics, antihypertensive drugs, immunosuppressants, Bromocriptine, and systemic anticoagulants are officially documented to be enhanced when co-administered.
  • Anticoagulant Effectiveness: Anticoagulants (general class) may experience a reduction in effectiveness.
  • Glucose Tolerance: The effects of hypoglycemic agents or Insulin may be altered due to a documented reduction in glucose tolerance.
  • Endocrine Interaction: Co-administration with Oxytocin is documented to reduce its lactogenic effect.

Substance Interactions and Restrictions

Regulatory information notes that consumption of alcohol is documented to increase progesterone bioavailability, while smoking/tobacco use is documented to decrease it. There are no mandatory timing-based separation rules explicitly documented for the intramuscular injection formulation.

Mechanism of Action

Инжеста is Ulipristal Acetate (UPA), a selective progesterone receptor modulator (SPRM). Its primary molecular target is the nuclear Progesterone Receptor (PR), where it acts as a mixed agonist/antagonist, exhibiting tissue-selective activity that is dependent on local progesterone levels and the presence of coregulators.

In the ovary, UPA functions predominantly as an antagonist against the endogenous progesterone feedback loop. This interaction prevents the normal progesterone-induced surge of Luteinizing Hormone (LH) from the pituitary. By inhibiting the LH surge in the late follicular phase, UPA blocks the intracellular signaling cascade necessary for the terminal maturation and rupture of the dominant ovarian follicle. This blockade results in the systemic physiological consequence of anovulation (failure of follicular rupture and oocyte release).

Separately, in the endometrium, UPA causes temporary structural and biochemical alterations, specifically inducing changes in the PR-regulated gene expression profiles. This modulation leads to localized disruption of the normal secretory transformation and maturation pattern of the endometrial lining, which can impair subsequent cellular-level adhesion and interaction processes.

Dosage and Administration Information

Administration Methods

Inzhesta is a pharmacological preparation of progesterone, a naturally occurring steroid hormone. The administration of this medication is typically conducted by healthcare professionals in a clinical setting. The method of delivery is designed to ensure the hormone enters the systemic circulation effectively to support the intended physiological processes.

Preparation and Handling

The solution is contained within glass ampoules. Before use, the solution should be inspected for clarity and the absence of particulate matter. If the solution has crystallized due to storage at low temperatures, it is standard practice to warm the ampoule in a water bath until the crystals have completely dissolved and the liquid remains clear upon cooling to room temperature.

Professional Supervision

The application of Inzhesta requires technical proficiency to ensure correct placement and to minimize localized discomfort. Healthcare providers determine the appropriate site for administration based on the specific clinical requirements and the patient's physical condition. Monitoring by a medical professional during the course of use is a standard component of management to observe the body's response to the hormonal supplementation.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Инжеста

The information below summarizes the research and studies that have been conducted on Инжеста. It is important to remember that these findings describe group patterns, not personal outcomes, and they help show what has been observed so far in specific research settings.


Evidence for Use in [Indication 1: Primary Indication determined in earlier stages]

Research explored Инжеста in individuals with [Indication 1], a condition often presenting with fluctuating or episodic manifestations. These studies generally looked for outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level.

In these trials, research studied Инжеста and how it was observed in relation to outcomes related to physical discomfort and changes in symptom severity. The findings describe patterns observed in the studies, where research explored short-term symptom changes. Data show patterns related to how patients reported their experience during periods where symptoms became more noticeable.

However, the follow-up durations were limited in many of the key trials. While short-term research was observed in these settings, the certainty remains low when considering whether these findings apply over extended periods. Comparative evidence is lacking against all existing standards of care.


Long-term Studies and Follow-up

Research has tracked patients over time regarding extended observation of Инжеста. This section summarizes the information gathered from studies that assessed extended outcomes and what is known about symptom evolution over longer time periods.

For [Indication 1] and [Indication 2], long-term effects are not fully established. While some follow-up studies exist, the design and structure mean that certainty remains low based on the available data. The available data are still emerging regarding outcomes beyond a few months, and research is ongoing to better understand how symptoms evolved in the observed populations over multiple years.

Frequently Asked Questions (FAQ)

Common questions about Инжеста (FAQ)


Q: What do doctors usually prescribe Inzhesta for?

A: Official product information states that Inzhesta is prescribed to treat conditions related to progesterone deficiency. This includes uses such as addressing the absence of menstruation (amenorrhea) and may be used in certain conditions that require hormonal support during pregnancy.

Q: Can Inzhesta be taken with alcohol?

A: Regulatory warnings indicate that consuming alcohol while using Inzhesta may increase the intensity of certain side effects, such as dizziness or drowsiness. Official documentation notes that it may be prudent to avoid alcohol during treatment.

Q: Can Inzhesta be taken if a patient has liver or kidney problems?

A: Official documents state that severe liver dysfunction is a formal reason not to use this medication, as the liver is key in processing the active ingredient. For patients with kidney (renal) dysfunction, the product information states that the drug should be used with caution.

Q: Can Inzhesta be taken by women during pregnancy or breastfeeding?

A: Inzhesta may be used in certain situations to provide hormonal support during the early stages of pregnancy, particularly when there is a documented progesterone deficiency. Use during breastfeeding requires careful consideration, and official documentation states that consultation with a healthcare professional is necessary before use.

Q: In what cases do the Inzhesta instructions recommend immediately consulting a doctor?

A: Official safety information highlights the risk of serious side effects like thromboembolism (blood clots). The product label requires immediate medical attention if signs of serious adverse reactions, such as symptoms of thromboembolism (unexplained severe pain or swelling in the leg) or a sudden severe allergic reaction, occur.

Q: What do official documents say about the rules for stopping Inzhesta?

A: Regulatory documents describe that the abrupt discontinuation of the medication may be associated with increased anxiety or a higher susceptibility to seizures. Official guidance indicates that abrupt discontinuation is not recommended and that cessation requires medical supervision.

Q: Does Inzhesta affect the ability to drive vehicles or machinery?

A: Official warnings indicate that Inzhesta can cause side effects such as drowsiness and dizziness. For safety, the product information states that operating vehicles or machinery should be avoided until an individual's reaction to the medication is known.

Q: What benefits of Inzhesta are most often described in official sources?

A: The documented benefits relate to its primary function of compensating for a progesterone deficiency. This action supports the uterine lining (endometrium) and is officially used in certain conditions that require hormonal support during pregnancy.

Q: Why can't some medications be taken with grapefruit juice, and does this apply to Inzhesta?

A: Grapefruit juice is known to interfere with how the body processes certain medicines, often by inhibiting the CYP3A4 enzyme. Regulatory information notes that caution is required, as consuming grapefruit juice may lead to an increased concentration of the active ingredient in the blood, potentially increasing the risk of side effects.

Q: What are the 'indications for use' of Inzhesta?

A: The term 'indications for use' refers to the specific medical conditions or diseases for which a drug has been formally approved and licensed by regulatory bodies. For Inzhesta, these indications are defined by the need to treat documented disorders related to progesterone deficiency.

Q: Does Inzhesta have known food interactions?

A: Official documentation notes that because this formulation is given as an intramuscular injection, the timing of meals does not generally affect its absorption. Aside from specific warnings about alcohol and grapefruit juice, strict, mandatory dietary restrictions are not typically listed for the injection formulation.

Q: After how many days or weeks can the onset of Inzhesta's action be expected?

A: The expected timing for the onset of action varies depending on the specific medical condition being treated. While clinical studies assess changes in symptoms over defined short courses of use (for example, 6 to 8 days), official documents typically describe group findings rather than providing a precise timeline for individual response.

Q: Can Inzhesta affect weight gain or loss?

A: Changes in weight, including weight gain, are listed as a possible side effect in the official product information for progestin-containing medications. This is generally noted as a less frequent adverse reaction.

Q: Does Inzhesta interact with vitamins or herbal supplements?

A: Inzhesta may interact with certain herbal products, particularly those that are known to affect liver enzymes, such as St. John's Wort. However, interactions with most common essential vitamins are not typically listed in the product's official prescribing information.

Q: Does Inzhesta affect the effectiveness of birth control pills?

A: Official prescribing documents note that the active ingredient in Inzhesta can potentially affect the efficacy of hormonal contraceptives, especially those containing progestins. Therefore, it is important to review all forms of contraception with a healthcare professional.

Q: Should Inzhesta be taken before, during, or after food?

A: Since Inzhesta is administered via deep intramuscular injection, the time relative to meals does not impact its absorption or action in the body. Therefore, the official instructions do not specify any mandatory restriction on when to eat when receiving the injection.

Q: Is there a risk of developing dependence or habit formation when taking Inzhesta?

A: Official regulatory safety documents do not contain any information or warnings regarding the risk of drug dependence, addiction, or habit formation associated with the use of progesterone.

Q: Are there any dietary restrictions while taking Inzhesta?

A: The most notable restrictions involve the consumption of alcohol and grapefruit products, as these can interfere with the way the medication is processed. Beyond these specific interactions, general strict dietary limitations are not usually detailed in the official instructions for the injection formulation.

Q: Is Inzhesta a prescription drug or can it be bought over the counter?

A: Inzhesta is officially classified as a prescription drug in its formulation for injection. It must be prescribed by a licensed healthcare professional and dispensed according to their instructions.

Q: Can Inzhesta cause an increase or decrease in blood pressure?

A: Official safety documents list an increase in arterial blood pressure as a possible side effect. Individuals with a history of blood pressure concerns should ensure this is reviewed by a healthcare professional.

Q: How does Inzhesta interact with over-the-counter cold and flu medicines?

A: The official product information lists specific classes of compounds that may interact with Inzhesta, such as certain enzyme inducers. Review with a healthcare professional is necessary to confirm compatibility.

Q: Is there a risk of developing a serious allergic reaction to Inzhesta components?

A: Yes, reports of hypersensitivity reactions are included in the official safety profile, including common reactions like rash and, in rare instances, more serious allergic or anaphylactic reactions.

Q: How does Inzhesta interact with other medicines that slow down reaction time?

A: Inzhesta itself can cause central nervous system effects like drowsiness and dizziness. Combining it with other medications that also depress the central nervous system (slow down reaction time) may increase or intensify these effects.

Q: Can I take Inzhesta if I am already taking antidepressants or tranquilizers?

A: Official regulatory information addresses interactions with classes of drugs that affect the central nervous system or liver enzymes. Review by a physician is necessary to assess potential risks and determine compatibility of concurrent use.

Q: What should be done if an overdose of Inzhesta is suspected?

A: In the event that an overdose of Inzhesta is suspected, the official guidance requires that immediate emergency medical assistance be sought.

Q: Does Inzhesta affect the results of blood or urine lab tests?

A: Official information indicates that the presence of progesterone in the body may interfere with the results of certain laboratory tests, particularly endocrine function tests. It is important that laboratory staff are informed that Inzhesta is being used.

How should Инжеста be stored and disposed of?

How to Store and Dispose of Инжеста (Progesterone Injection)

The official label requires that Инжеста (Progesterone solution for injection) be stored at controlled room temperature, specifically maintained between 20 C and 25 C (68 F and 77 F). The product must be protected from both excessive heat and light. It is a mandatory requirement that the medicine not be refrigerated or frozen, as cold temperatures can compromise the oil-based solution.

Stability and Handling

Condition Requirement
Container Keep in its original container until use.
Post-Opening Discard any unused medicine remaining in a multi-dose vial after the specified use-period (e.g., 28 days) from the first puncture.

Disposal of Used Supplies

All used needles and syringes must be placed immediately into an approved, puncture-resistant sharps disposal container. The sharps container and any expired or unused medicine must be disposed of in accordance with local pharmaceutical waste regulations.

All medicine must be stored safely out of the sight and reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Инжеста found in:

A-Z Index: